This article is more than 5 years old. Information may no longer be current.

Biotech drug may help treat wet AMD, animal study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An antisense drug designed to block growth hormone receptor expression has been found to ward off wet age-related macular degeneration in mice, the drug's developer said in a press release. ATL1103 was tested on mice at the University of Queensland in Australia, according to Antisense Therapeutics. By targeting growth hormone receptors, ATL1103 reduces levels of insulin-like growth factor-1, according to the press release.

Development of AMD has been linked to excessive levels of IGF-1, as has diabetic retinopathy, the company said.

Antisense Therapeutics noted the drug will enter human trials soon.